Rapport Therapeutics (RAPP) Other Non-Current Liabilities (2023 - 2024)
Rapport Therapeutics (RAPP) reported Other Non-Current Liabilities of $9.4 million for Q4 2024, up 124.57% year-over-year from $4.2 million in Q1 2024, and up 124.57% quarter-over-quarter from $4.2 million in Q4 2023.
Rapport Therapeutics (RAPP) Other Non-Current Liabilities (2023 - 2024) Analysis & Trends
Rapport Therapeutics (RAPP) has 2 years of Other Non-Current Liabilities data on file, last reported at $9.4 million in Q4 2024.
- Other Non-Current Liabilities for Q4 2024 came in at $9.4 million, up 124.57% year-over-year; the trailing twelve-month figure through Dec 2024 was $9.4 million (up 124.57% YoY), and the FY2024 annual result was $9.4 million, up 124.57% from the prior year.
- Other Non-Current Liabilities grew to $9.4 million in Q4 2024 per RAPP's latest filing, from $4.2 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $9.4 million in Q4 2024 and troughed at $4.2 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Rapport Therapeutics | 1.66 Bn | 1.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 9.43 Mn |
| Dec 31, 2023 | 4.20 Mn |